Embolization Agents Market Size ($4,525.75Mn by 2028) Lead by Coil Segment (7.6% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
22 oct. 2021 08h22 HE
|
The Insight Partners
New York, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The new research study on the Embolization Agents Market Size and Forecast to 2028 by Product (Coils, Plugs, Beads/Particles, Detachable Balloons, Glue,...
Worldwide Diltiazem Industry to 2028 - Increase in Cardiovascular Disease Incidence is Driving Growth
21 oct. 2021 06h58 HE
|
Research and Markets
Dublin, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The "Global Diltiazem Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Capsules, Injection, and Tablets); Application (Angina,...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
16 sept. 2021 08h30 HE
|
Lexaria Bioscience Corp.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System
15 sept. 2021 08h30 HE
|
Lexaria Bioscience Corp.
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation
06 août 2021 08h30 HE
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment
04 août 2021 08h30 HE
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
16 juin 2021 08h00 HE
|
KBP BioSciences
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...
Houston Officially Welcomes the Karya Kares Clinic
18 mai 2021 13h56 HE
|
Karya Property Management
Houston, Texas, May 18, 2021 (GLOBE NEWSWIRE) -- Located inside Bella Vista Apartments complex, a residential apartment community centered in the Dairy Ashford region of Houston, the Karya Kares...
Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress
22 avr. 2021 16h32 HE
|
Cardiometabolic Health Congress
Boca Raton, FL, April 22, 2021 (GLOBE NEWSWIRE) -- Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress Top Experts Convene to Discuss the Syndemic of COVID-19 &...
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
10 déc. 2020 04h13 HE
|
Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...